Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 13.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Heart-Lung Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 51 48 27 33 29 40 35 31 31 27
Tx with Antirejection Treatments 18 16 4 8 8 12 10 13 6 6
Antibodies Any in Category 5.6% 18.8% 0.0% 0.0% 12.5% 16.7% 0.0% 38.5% 0.0% 16.7%
Atgam/NRATG/NRATS 0.0% 6.3% 0.0% 0.0% 12.5% 0.0% 0.0% 15.4% 0.0% 0.0%
Thymoglobulin 5.6% 0.0% 0.0% 0.0% 0.0% 16.7% 0.0% 15.4% 0.0% 16.7%
Zenapax 0.0% 12.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Simulect 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.7% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.7% 0.0% 0.0%
Corticosteroids Any in Category 94.4% 93.8% 100.0% 100.0% 62.5% 100.0% 100.0% 100.0% 100.0% 100.0%
Steroids 94.4% 93.8% 100.0% 100.0% 62.5% 100.0% 100.0% 100.0% 100.0% 100.0%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.